Europe's medicines regulator on Friday recommended granting a marketing authorization to Biogen's (BIIB.O) drug for the deadly and progressive neurodegenerative disease known as amyotrophic lateral sclerosis (ALS).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,